Development of a collaborative professional group for HIV pharmacists: experience from the Canadian HIV/AIDS Pharmacists Network

Can switching to doravirine/lamivudine/tenofovir DF halt or reverse INSTI-associated weight gain?

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada·2026

Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug-drug interactions (ACCURATE-DDI).

AIDS (London, England)·2026

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

"Weight and See": Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type and Does Not Predict Subsequent Weight Trajectory.

Open forum infectious diseases·2025

Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary.

Pharmacotherapy·2024